$ICPT Headlines This shocking strategy will save your

New Post Public Reply Private Reply Replies (1) Message Board

Jan 28, 2014 at 10:54 AM

$ICPT Headlines

This shocking strategy will save your portfolio 6:01 a.m. Jan. 15, 2014 - Jeff Reeves
Alnylam shares settle down after 40% gain; analysts are skeptical 1:16 p.m. Jan. 14, 2014 - Russ Britt
Intercept, Intuitive take diverging paths on the market roller coaster 10:51 a.m. Jan. 14, 2014 - Russ Britt
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Beam up on Suntory deal; Elliott report lifts Juniper 4:18 p.m. Jan. 13, 2014 - Sue Chang
Merck shares hit 52-week high on drug hopes, plans for cutbacks 12:31 p.m. Jan. 13, 2014 - Russ Britt
Intercept, Lululemon, SodaStream shares slump 10:22 a.m. Jan. 13, 2014 - Saumya Vaishampayan
S&P 500 gains for week; builder stocks rally as yields fall; the wonder of liver-drug stocks (live blog recap) 10:15 a.m. Jan. 13, 2014 - blogs.marketwatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 9:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept shares trip short-sale circuit breaker 9:32 a.m. Jan. 13, 2014 - Laura Mandaro
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Banks, hedge funds and what Citi has to tell its rich clients 7:47 a.m. Jan. 13, 2014 - Shawn Langlois
Alcoa tops S&P losers, Twitter extends losing streak 4:29 p.m. Jan. 10, 2014 - Sue Chang
Macy’s up on restructuring; Apple and Samsung to talk 4:40 p.m. Jan. 9, 2014 - Sue Chang
Stock record? Intercept Pharma up nearly 300% on drug test results 2:14 p.m. Jan. 9, 2014 - Russ Britt
Intercept Pharma, Kythera take off in IPOs 10:53 a.m. Oct. 11, 2012 - MarketWatch.com
Intercept Pharma, Kythera take off in IPOs 10:34 a.m. Oct. 11, 2012 - MarketWatch.com
In the IPO desert, Thursday brings rain 9:42 a.m. Oct. 11, 2012 - MarketWatch
Intercept Pharma 5M-share IPO prices at high end 7:06 a.m. Oct. 11, 2012 - MarketWatch.com
Stocks to watch Thursday: Ruby Tuesday, Realogy 5:44 a.m. Oct. 11, 2012 - MarketWatch

Is The Healthcare Sector Pulling Back Or Crashing? 5:40 a.m. Today - Seeking Alpha
Liver Drug Race: Intercept Pharma Vs. Rivals 7:24 p.m. Jan. 26, 2014 - Seeking Alpha
Why It Could Pay Off To Look At The Big Picture Of Intercept Pharmaceuticals 3:47 p.m. Jan. 24, 2014 - Seeking Alpha
Amidst Huge Unknowns, Conatus Pharmaceuticals Worth A Closer Look 9:30 a.m. Jan. 24, 2014 - Seeking Alpha
Cramer's Lightning Round - I'm Going To Play SolarCity (1/23/14) 6:24 a.m. Jan. 24, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Buy, Buy, Buy Visa 6:00 a.m. Jan. 24, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Markets Behaving Badly 8:27 p.m. Jan. 23, 2014 - TheStreet.com
5 Drugs Stocks Nudging The Industry Higher 12:03 p.m. Jan. 22, 2014 - TheStreet.com
Strong Upward Pre-Market Activity For Intercept Pharmaceuticals (ICPT) 8:24 a.m. Jan. 22, 2014 - TheStreet.com
It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013 7:00 a.m. Jan. 21, 2014 - TheStreet.com
Intercept Pharmaceuticals: 6 Different Insiders Have Sold Shares This Year 3:38 a.m. Jan. 21, 2014 - Seeking Alpha
3 Sector ETFs Surging to Start 2014 - ETF News And Commentary 10:00 a.m. Jan. 20, 2014 - Zacks.com
My Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare Conference 1:50 p.m. Jan. 17, 2014 - TheStreet.com
4 Biotech Stocks Making Big Moves 1:41 p.m. Jan. 17, 2014 - Wall St. Cheat Sheet
3 Biotech Stocks Where Momentum is Alive and Well 8:47 a.m. Jan. 17, 2014 - InvestorPlace.com
5 Dumbest Things on Wall Street This Week 7:00 a.m. Jan. 17, 2014 - TheStreet.com
3 Critical Factors For Intercept Bulls Now 4:02 a.m. Jan. 16, 2014 - Seeking Alpha
Athersys: Why Did Shareholders Come Knocking At The Door Once Again? 3:15 p.m. Jan. 15, 2014 - Seeking Alpha
Intercept Pharma cools off after presentation 11:04 a.m. Jan. 15, 2014 - Seeking Alpha
Today's Dead Cat Bounce Stock Is Intercept Pharmaceuticals (ICPT) 9:45 a.m. Jan. 15, 2014 - TheStreet.com

Intercept Pharmaceuticals, Inc. [ICPT] to Ring The NASDAQ Stock Market Closing Bell 10:00 a.m. Jan. 22, 2014 - GlobeNewswire
Harwood Feffer LLP Announces Investigation of Intercept Pharmaceuticals, Inc. 8:00 p.m. Jan. 15, 2014 - PR Newswire - PRF
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Intercept Pharmaceuticals, Inc. 2:03 p.m. Jan. 14, 2014 - BusinessWire - BZX
Small Cap Buzz: GW Pharmaceuticals, Intercept Pharmaceuticals, Medbox Inc, GreenGro Technologies 11:19 a.m. Jan. 13, 2014 - ACCESSWIRE
Intercept Reports Additional Details About FLINT Trial Provided by NIDDK 6:06 p.m. Jan. 12, 2014 - GlobeNewswire
Intercept to Present at the J.P. Morgan Healthcare Conference 6:31 p.m. Jan. 10, 2014 - GlobeNewswire
Intercept Provides 2013 Year-End Update and 2014 Anticipated Milestones 4:05 p.m. Jan. 9, 2014 - GlobeNewswire
Intercept Provides 2013 Year-End Update and 2014 Anticipated Milestones 4:05 p.m. Jan. 9, 2014 - GlobeNewswire
Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology 7:33 a.m. Jan. 9, 2014 - GlobeNewswire
Intercept Pharmaceuticals to Provide 2013 Update on Clinical Programs for Obeticholic Acid on January 9 4:05 p.m. Jan. 2, 2014 - GlobeNewswire
Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept 8:00 a.m. Dec. 18, 2013 - PR Newswire
INTERCEPT PHARMACEUTICALS, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Intercept Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty 6:31 p.m. Dec. 9, 2013 - PR Newswire
Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals 8:00 a.m. Nov. 20, 2013 - PR Newswire
Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results 6:05 a.m. Nov. 14, 2013 - PR Newswire
Trial Results Presentations, Public Offerings, Acquisitions and Extension Study Results - Research Report on Medtronic, Steris, Intercept, Wright, and Synageva 7:00 a.m. Oct. 23, 2013 - PR Newswire
Intercept Announces Pricing of Public Offering of Common Stock By Selling Stockholders 8:02 p.m. Oct. 8, 2013 - PR Newswire
Keryx Biopharmaceuticals, Inc. Announces Appointment of Daniel P. Regan to Board of Directors 7:30 a.m. Oct. 4, 2013 - GlobeNewswire
Business Strategy, Partnerships, Presentation, and Appointment - Research Report on Merck, GSK, Sanofi, Intercept, and KYTHERA 7:00 a.m. Oct. 4, 2013 - PR Newswire
Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting 3:05 p.m. Oct. 1, 2013 - PR Newswire
Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results 5:00 a.m. Aug. 13, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...